RNF5 and RNF185 ubiquitinate CFTR F508del

Stable Identifier
R-HSA-8866856
Type
Reaction [transition]
Species
Homo sapiens
Compartment
endoplasmic reticulum membrane
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
RNF5 and RNF185 ubiquitinate CFTR F508del
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
RNF5 and RNF185 ubiquitinate CFTR F508del as part of the retrotranslocon that targets the receptor for degradation through the ERAD pathway. Both depletion of the E3 ligases by siRNA and expression of a catalytically inactive form of the enzyme strongly inhibits CFTR degradation (El Khouri et al, 2013; Younger et al, 2006).
Literature References
PubMed ID Title Journal Year
24019521 RNF185 is a novel E3 ligase of endoplasmic reticulum-associated degradation (ERAD) that targets cystic fibrosis transmembrane conductance regulator (CFTR)

El Khouri, E, Toledano, MB, Le Pavec, G, Delaunay-Moisan, A

J. Biol. Chem. 2013
16901789 Sequential quality-control checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator

Fan, CY, Ren, HY, Rosser, MF, Younger, JM, Cyr, DM, Turnbull, EL, Chen, L, Patterson, C

Cell 2006
Participants
Input
Output
Participates
as an event of
Catalyst Activity

ubiquitin protein ligase activity of CFTR F508del:ERAD complex [endoplasmic reticulum membrane]

Physical Entity
CFTR F508del:ERAD complex [endoplasmic reticulum membrane] (Homo sapiens)
Activity
ubiquitin protein ligase activity (GO:0061630)
Normal reaction
RNF5 and RNF185 ubiquitinate misfolded CFTR (Homo sapiens)
Functional status

Gain of function of CFTR F508del:ERAD complex [endoplasmic reticulum membrane]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cystic fibrosis DOID:1485 mucoviscidosis, CF
Authored
Rothfels, K  (2016-04-02)
Reviewed
D'Eustachio, P  (2016-04-23)
Created
Rothfels, K  (2016-04-04)
Cite Us!